Literature DB >> 20813390

HPV-16 E5 down-regulates expression of surface HLA class I and reduces recognition by CD8 T cells.

M S Campo1, S V Graham, M S Cortese, G H Ashrafi, E H Araibi, E S Dornan, K Miners, C Nunes, S Man.   

Abstract

HPV-16 is the major causes of cervical cancer. Persistence of infection is a necessary event for progression of the infection to cancer. Among other factors, virus persistence is due the viral proteins fighting the immune response. HPV-16 E5 down-regulates MHC/HLA class I, which is much reduced on the cell surface and accumulates in the Golgi apparatus in cells expressing E5. This effect is observed also in W12 cells, which mimic early cervical intraepithelial progression to cervical cancer. The functional effect of MHC I down-regulation on human CD8 T cells is not known, because of the need for HLA-matched, HPV-specific T cells that recognise E5 expressing-cells. Here we employ a heterologous cell/MHC I system which uses mouse cells expressing both E5 and HLA-A2, and A2-restricted CTLs; we show that the E5-induced reduction of HLA-A2 has a functional impact by reducing recognition of E5 expressing cells by HPV specific CD8+ T cells.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20813390     DOI: 10.1016/j.virol.2010.07.044

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  49 in total

1.  Tailored immunotherapy for HPV positive head and neck squamous cell cancer.

Authors:  Neil Gildener-Leapman; John Lee; Robert L Ferris
Journal:  Oral Oncol       Date:  2013-10-11       Impact factor: 5.337

Review 2.  Evasion of host immune defenses by human papillomavirus.

Authors:  Joseph A Westrich; Cody J Warren; Dohun Pyeon
Journal:  Virus Res       Date:  2016-11-24       Impact factor: 3.303

3.  HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.

Authors:  Sayuri Miyauchi; P Dominick Sanders; Kripa Guram; Sangwoo S Kim; Francesca Paolini; Aldo Venuti; Ezra E W Cohen; J Silvio Gutkind; Joseph A Califano; Andrew B Sharabi
Journal:  Cancer Res       Date:  2019-12-17       Impact factor: 12.701

Review 4.  [The innate immune system in oropharyngeal squamous cell carcinoma : Immune modulation by HPV].

Authors:  S Wagner; H Böckmann; S Gattenlöhner; J P Klussmann; C Wittekindt
Journal:  HNO       Date:  2018-04       Impact factor: 1.284

5.  Effect of human papillomavirus infection on the immune system and its role in the course of cervical cancer.

Authors:  Dan Song; Hong Li; Haibo Li; Jianrong Dai
Journal:  Oncol Lett       Date:  2015-05-29       Impact factor: 2.967

6.  A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN).

Authors:  Dan P Zandberg; Sandra Rollins; Olga Goloubeva; Robert E Morales; Ming Tan; Rodney Taylor; Jeffrey S Wolf; Lisa M Schumaker; Kevin J Cullen; Ann Zimrin; Robert Ord; Joshua E Lubek; Mohan Suntharalingam; John C Papadimitriou; Dean Mann; Scott E Strome; Martin J Edelman
Journal:  Cancer Immunol Immunother       Date:  2014-12-24       Impact factor: 6.968

Review 7.  The Interaction Between Human Papillomaviruses and the Stromal Microenvironment.

Authors:  B Woodby; M Scott; J Bodily
Journal:  Prog Mol Biol Transl Sci       Date:  2016-10-11       Impact factor: 3.622

8.  Reduced expression of members of the mhc-i antigen processing machinery in ethnic Uighur women with cervical cancer in the Xinjiang region of China.

Authors:  A Haimiti; Y Hailiman; A Gulina; J Du; Z Hao; X L Rong; A Zainuer; W Qin; S Lalai
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

Review 9.  Mechanisms of persistence by small DNA tumor viruses.

Authors:  Nathan A Krump; Wei Liu; Jianxin You
Journal:  Curr Opin Virol       Date:  2018-10-01       Impact factor: 7.090

10.  Langerhans cells from women with cervical precancerous lesions become functionally responsive against human papillomavirus after activation with stabilized Poly-I:C.

Authors:  Diane M Da Silva; Andrew W Woodham; Joseph G Skeate; Laurie K Rijkee; Julia R Taylor; Heike E Brand; Laila I Muderspach; Lynda D Roman; Annie A Yessaian; Huyen Q Pham; Koji Matsuo; Yvonne G Lin; Greg M McKee; Andres M Salazar; W Martin Kast
Journal:  Clin Immunol       Date:  2015-09-08       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.